Dosing & Administration of Thrombate III
In general, it is desirable to raise the patient's AT level to normal (100%) and maintain this level for 2 to 8
days, depending on the indication for treatment, type and extent of surgery, patient's medical condition and
history, and physician's judgment. As a general recommendation, a starting treatment program includes:
| |
1. |
|
An initial loading dose of Thrombate III calculated to elevate the plasma AT level to 120%, based on an expected 1.4% increase above baseline activity level per IU/kg of Thrombate III administered. An initial increase in the plasma AT level to 120%, rather than 100%, is desirable to compensate for early declines following the initial loading dose and to obviate the need for a second dose of AT within a few hours of the initial treatment.
|
Dose Calculation Example
AT = antithrombin
*Expressed as percent of normal level based on functional AT assay.
Click Here to Try Out the Dosing Calculator
| |
2. |
|
Measurement of plasma AT levels should be obtained preinfusion (baseline), 20 minutes postinfusion (peak), every 12 hours postinfusion, and preceding the next infusion (trough). Plasma levels between 80% and 120% may be maintained by administration of maintenance doses of 60% of the initial loading dose, administered every 24 hours. Adjustments in the maintenance dose and/or interval between doses should be made based on actual plasma AT levels achieved.
|
Input the variables and let the calculator tell you how much Thrombate III you will need.
These dosing recommendations are intended only as a general guideline for therapy. The exact loading and maintenance doses and dosing intervals should be individualized for each patient based on clinical conditions, response to therapy, and actual plasma AT levels achieved.
Special Considerations
The life of circulating antithrombin can be significantly shortened following some surgeries,
when there is hemorrhage or acute thrombosis, and after intravenous heparin administration. In
these cases, additional monitoring is warranted, and more frequent Thrombate III administration is necessary.
Reconstitution
Be sure to follow the instructions included with the product and use the special sterile
filter needle supplied with Thrombate III. Note: Aseptic technique should be carefully
followed. All needles and vial tops that will come into contact with the product to be
administered via the intravenous route should not come in contact with any nonsterile
surface. Any contaminated needles should be discarded by placing in a puncture-proof
container and new equipment should be used.
How Thrombate III Is Supplied
Thrombate III is supplied in single use vials of 500 IU: NDC 13533-603-20.
A volume of Sterile Water for Injection, a sterile double-ended transfer needle, and a filter needle are included with each vial.
For clinical questions about Thrombate III, please contact Talecris Clinical Communications: 1-800-520-2807.
To order Thrombate III, view our list of distributors.
See Efficacy and Safety Information for Thrombate III.
Important Safety Information
Thrombate III therapy has demonstrated a low occurrence of side effects. In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and a foul taste in the mouth. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated. Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.
Please see full Prescribing Information for Thrombate III.
|